Liquidia Corporation
42.65USD
+2.9600 (+7.46%)
Computing valuation metrics…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on LQDA.
Valuation
P/E (TTM)
27.54x
P/E (Forward)
19.50x
EV/EBITDA
21.86x
EV/Revenue
8.24x
P/S (TTM)
8.47x
P/B
19.57x
FCF Yield
3.95%
Dividend Yield
0.00%
Gross Margin
1.82%
Operating Margin
37.39%
Net Margin
30.74%
Peer Comparison — Drug Manufacturers - Specialty & Generic
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| LQDALiquidia Corporation | $3.82B | 27.54x | 21.86x | 3.95% | 1842.73% | 0.00% |
| TEVATeva Pharmaceutical Industries Limited | $45.96B | 65.68x | 13.86x | 4.83% | -0.80% | 0.00% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $33.48B |
| 13.33x |
| 10.10x |
| 6.02% |
| -0.20% |
| 2.62% |
| UTHRUnited Therapeutics Corporation | $25.20B | 21.04x | 15.06x | 2.21% | -1.90% | 0.00% |
| VTRSViatris Inc. | $20.67B | — | 7.64x | 12.95% | 4.90% | 2.67% |
| HIMSHims & Hers Health, Inc. | $6.47B | — | — | 13.14% | 38.20% | 0.00% |
| KNSAKiniksa Pharmaceuticals International, plc | $5.90B | 77.51x | 53.60x | 2.14% | 55.40% | 0.00% |
| RGCRegencell Bioscience Holdings Limited | $3.80B | — | — | -0.08% | — | 0.00% |
| AMLXAmylyx Pharmaceuticals, Inc. | $3.41B | — | — | -2.26% | — | 0.00% |